GlassScriptPhysician profile
Kathryn Lynn Cray
NPI 1629387592
$744.33
in general payments reported to CMS, 2019-2025
10 companies · $298 in 2025
The $298 reported for 2025 was more than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $17.37 · 2023: $159 · 2024: $270 · 2025: $298.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $727.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $726.96 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Dexcom, INC. | $269.78 | 2021-2025 | Dexcom G6 Transmitter |
| Tandem Diabetes Care, INC. | $119.92 | 2024-2025 | T:Slim X2 Insulin Pump With Control-Iq |
| Medtronic, INC. | $78.36 | 2023-2024 | Minimed 780g |
| Sanofi-Aventis U.S. LLC | $57.94 | 2024-2025 | |
| Lilly USA, LLC | $52.82 | 2024 | Mounjaro, Zepbound |
| Novo Nordisk INC | $47.92 | 2024-2025 | Ozempic, Rybelsus |
| Sequel Med Tech, LLC | $39.15 | 2025 | Twiist |
| Beta Bionics, INC. | $30.58 | 2023-2024 | Ilet Bionic Pancreas |
| Abbott Laboratories | $24.88 | 2023 | Freestyle Libre 2 |
| Embecta Corp. | $22.98 | 2023 | Bd Nano 2nd Gen Pen Needle |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kathryn Cray listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.